Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.

Molecular therapy : the journal of the American Society of Gene Therapy - 5 May 2021

Nakatake Motomu, Kuwano Nozomi, Kaitsurumaru Emi, Kurosaki Hajime, Nakamura Takafumi

Abstract excerpt

Oncolytic viruses induce antitumor immunity following direct viral oncolysis. However, their therapeutic effects are limited in distant untreated tumors because their antitumor function depends on indirect antitumor immunity. Here, we generated a novel fusogenic oncolytic vaccinia virus (FUVAC) and compared its antitumor activity with that of its parental non-fusogenic virus. Compared with the parent, FUVAC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Vaccinia virus

Share to Virus Internalization

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33348052
DOI: 10.1016/j.ymthe.2020.12.024
PMCID: PMC8116573

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.PMID 33348052Read ↗

Elucidating Mechanisms of Antitumor Immunity Mediated by Live Oncolytic Vaccinia and Heat-Inactivated VacciniaSemantic proximity Read ↗

Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?Semantic proximity Read ↗

Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancerSemantic proximity Read ↗

Oncolytic Virotherapy: From Bench to BedsideSemantic proximity Read ↗

Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.Semantic proximity Read ↗

The oncolytic virus ΔPK has multimodal anti-tumor activity.Semantic proximity Read ↗

Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.Semantic proximity Read ↗

Oncolytic virotherapy: the questions and the promiseSemantic proximity Read ↗

Synergistic Interaction Between Oncolytic Viruses Augments Tumor KillingSemantic proximity Read ↗

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerSemantic proximity Read ↗

Intratumoral delivery of engineered recombinant modified vaccinia virus Ankara expressing Flt3L and OX40L generates potent antitumor immunity through activating the cGAS/STING pathway and depleting tumor-infiltrating regulatory T cellsSemantic proximity Read ↗

Exploring Reovirus Plasticity for Improving Its Use as Oncolytic VirusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.